4503.T
Astellas Pharma Inc.
4503.T
(2.5)1.680,50 JPY
0.97% ROA
1.08% ROE
179.95x PER
3.117.036.094.371,00 JPY
59.21% DER
4.13% Yield
1.02% NPM
Astellas Pharma Inc. Stock Analysis
Astellas Pharma Inc. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
DER
The stock has a minimal amount of debt (23%) relative to its ownership, showcasing a strong financial position and lower risk for investors. |
|
| 2 |
Dividend Growth
The company's dividend growth has consistently increased every year in the last five years, indicating a strong track record of positive returns for investors. |
|
| 3 |
ROE
The stock's ROE falls within an average range (6.3%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity. |
|
| 4 |
ROA
The stock's ROA (6.55%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits. |
|
| 5 |
PBV
The stock's PBV ratio (2.11x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities. |
|
| 6 |
Assets Growth
Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice. |
|
| 7 |
Dividend
The company's consistent dividend payments over the past three years indicate a strong commitment to delivering returns to investors. |
|
| 8 |
Buffet Intrinsic Value
The company's stock seems undervalued (23.743) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price. |
|
| 9 |
Revenue Growth
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice. |
|
| 10 |
Net Profit Growth
Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors. |
|
| 11 |
Graham Number
Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice. |
Astellas Pharma Inc. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Hold |
| 2 | MACD | Buy |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Sell |
Astellas Pharma Inc. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2003 | 511.208.000.000 | |
| 2004 | 447.051.000.000 | -14.35% |
| 2005 | 879.362.000.000 | 49.16% |
| 2006 | 920.624.000.000 | 4.48% |
| 2007 | 972.586.000.000 | 5.34% |
| 2008 | 965.698.000.000 | -0.71% |
| 2009 | 974.877.000.000 | 0.94% |
| 2010 | 953.947.000.000 | -2.19% |
| 2011 | 969.387.000.000 | 1.59% |
| 2012 | 1.005.611.000.000 | 3.6% |
| 2013 | 1.139.909.000.000 | 11.78% |
| 2014 | 1.247.259.000.000 | 8.61% |
| 2015 | 1.372.706.000.000 | 9.14% |
| 2016 | 1.311.665.000.000 | -4.65% |
| 2017 | 1.300.316.000.000 | -0.87% |
| 2018 | 1.306.348.000.000 | 0.46% |
| 2019 | 1.300.843.000.000 | -0.42% |
| 2020 | 1.249.528.000.000 | -4.11% |
| 2021 | 1.296.163.000.000 | 3.6% |
| 2022 | 1.518.619.000.000 | 14.65% |
| 2023 | 1.568.588.000.000 | 3.19% |
| 2023 | 1.603.672.000.000 | 2.19% |
| 2024 | 1.892.496.000.000 | 15.26% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2003 | 0 | |
| 2004 | 0 | 0% |
| 2005 | 0 | 0% |
| 2006 | 0 | 0% |
| 2007 | 0 | 0% |
| 2008 | 159.058.000.000 | 100% |
| 2009 | 195.570.000.000 | 18.67% |
| 2010 | 0 | 0% |
| 2011 | 0 | 0% |
| 2012 | 181.955.000.000 | 100% |
| 2013 | 191.460.000.000 | 4.96% |
| 2014 | 206.594.000.000 | 7.33% |
| 2015 | 225.665.000.000 | 8.45% |
| 2016 | 208.129.000.000 | -8.43% |
| 2017 | 220.781.000.000 | 5.73% |
| 2018 | 208.682.000.000 | -5.8% |
| 2019 | 224.226.000.000 | 6.93% |
| 2020 | 224.489.000.000 | 0.12% |
| 2021 | 246.010.000.000 | 8.75% |
| 2022 | 276.128.000.000 | 10.91% |
| 2023 | 309.420.000.000 | 10.76% |
| 2023 | 294.187.000.000 | -5.18% |
| 2024 | 347.284.000.000 | 15.29% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2003 | 236.457.000.000 | |
| 2004 | 196.990.000.000 | -20.04% |
| 2005 | 413.345.000.000 | 52.34% |
| 2006 | 446.047.000.000 | 7.33% |
| 2007 | 417.340.000.000 | -6.88% |
| 2008 | 23.035.000.000 | -1711.76% |
| 2009 | 21.761.000.000 | -5.85% |
| 2010 | 0 | 0% |
| 2011 | 0 | 0% |
| 2012 | 259.163.000.000 | 100% |
| 2013 | 397.018.000.000 | 34.72% |
| 2014 | 452.522.000.000 | 12.27% |
| 2015 | 500.359.000.000 | 9.56% |
| 2016 | 470.777.000.000 | -6.28% |
| 2017 | 478.330.000.000 | 1.58% |
| 2018 | 490.263.000.000 | 2.43% |
| 2019 | 499.295.000.000 | 1.81% |
| 2020 | 504.316.000.000 | 1% |
| 2021 | 548.840.000.000 | 8.11% |
| 2022 | 630.272.000.000 | 12.92% |
| 2023 | 717.120.000.000 | 12.11% |
| 2023 | 740.110.000.000 | 3.11% |
| 2024 | 0 | 0% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2003 | 129.010.000.000 | |
| 2004 | 141.380.000.000 | 8.75% |
| 2005 | 238.952.000.000 | 40.83% |
| 2006 | 236.281.000.000 | -1.13% |
| 2007 | 312.988.000.000 | 24.51% |
| 2008 | 387.730.000.000 | 19.28% |
| 2009 | 331.408.000.000 | -16.99% |
| 2010 | 196.429.000.000 | -68.72% |
| 2011 | 200.728.000.000 | 2.14% |
| 2012 | 215.282.000.000 | 6.76% |
| 2013 | 187.937.000.000 | -14.55% |
| 2014 | 258.235.000.000 | 27.22% |
| 2015 | 332.585.000.000 | 22.36% |
| 2016 | 347.536.000.000 | 4.3% |
| 2017 | 284.758.000.000 | -22.05% |
| 2018 | 313.727.000.000 | 9.23% |
| 2019 | 314.750.000.000 | 0.33% |
| 2020 | 220.311.000.000 | -42.87% |
| 2021 | 217.285.000.000 | -1.39% |
| 2022 | 246.666.000.000 | 11.91% |
| 2023 | 148.808.000.000 | -65.76% |
| 2023 | 335.910.000.000 | 55.7% |
| 2024 | 414.348.000.000 | 18.93% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2003 | 337.417.000.000 | |
| 2004 | 305.880.000.000 | -10.31% |
| 2005 | 606.365.000.000 | 49.56% |
| 2006 | 636.561.000.000 | 4.74% |
| 2007 | 693.244.000.000 | 8.18% |
| 2008 | 701.268.000.000 | 1.14% |
| 2009 | 685.637.000.000 | -2.28% |
| 2010 | 657.975.000.000 | -4.2% |
| 2011 | 650.755.000.000 | -1.11% |
| 2012 | 681.484.000.000 | 4.51% |
| 2013 | 809.281.000.000 | 15.79% |
| 2014 | 914.062.000.000 | 11.46% |
| 2015 | 1.037.110.000.000 | 11.86% |
| 2016 | 991.162.000.000 | -4.64% |
| 2017 | 1.006.066.000.000 | 1.48% |
| 2018 | 1.014.298.000.000 | 0.81% |
| 2019 | 1.024.104.000.000 | 0.96% |
| 2020 | 1.003.465.000.000 | -2.06% |
| 2021 | 1.043.154.000.000 | 3.8% |
| 2022 | 1.230.266.000.000 | 15.21% |
| 2023 | 1.270.944.000.000 | 3.2% |
| 2023 | 1.212.367.000.000 | -4.83% |
| 2024 | 1.527.952.000.000 | 20.65% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2003 | 60.058.000.000 | |
| 2004 | 33.717.000.000 | -78.12% |
| 2005 | 103.659.000.000 | 67.47% |
| 2006 | 131.286.000.000 | 21.04% |
| 2007 | 177.438.000.000 | 26.01% |
| 2008 | 170.986.000.000 | -3.77% |
| 2009 | 122.257.000.000 | -39.86% |
| 2010 | 67.650.000.000 | -80.72% |
| 2011 | 78.230.000.000 | 13.52% |
| 2012 | 82.851.000.000 | 5.58% |
| 2013 | 90.874.000.000 | 8.83% |
| 2014 | 135.856.000.000 | 33.11% |
| 2015 | 193.687.000.000 | 29.86% |
| 2016 | 218.701.000.000 | 11.44% |
| 2017 | 164.679.000.000 | -32.8% |
| 2018 | 222.265.000.000 | 25.91% |
| 2019 | 195.411.000.000 | -13.74% |
| 2020 | 120.589.000.000 | -62.05% |
| 2021 | 124.086.000.000 | 2.82% |
| 2022 | 98.714.000.000 | -25.7% |
| 2023 | -5.836.000.000 | 1791.47% |
| 2023 | 17.045.000.000 | 134.24% |
| 2024 | 150.412.000.000 | 88.67% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2003 | 24 | |
| 2004 | 19 | -27.78% |
| 2005 | 36 | 50% |
| 2006 | 47 | 21.74% |
| 2007 | 70 | 33.33% |
| 2008 | 71 | 2.82% |
| 2009 | 52 | -36.54% |
| 2010 | 29 | -79.31% |
| 2011 | 8 | -262.5% |
| 2012 | 32 | 75% |
| 2013 | 40 | 20% |
| 2014 | 62 | 34.43% |
| 2015 | 90 | 31.46% |
| 2016 | 104 | 13.59% |
| 2017 | 81 | -27.16% |
| 2018 | 115 | 29.57% |
| 2019 | 104 | -10.58% |
| 2020 | 65 | -62.5% |
| 2021 | 67 | 4.48% |
| 2022 | 54 | -24.07% |
| 2023 | -3 | 1900% |
| 2023 | 10 | 133.33% |
| 2024 | 84 | 89.29% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2003 | 31.243.000.000 | |
| 2004 | 39.932.000.000 | 21.76% |
| 2005 | 118.697.000.000 | 66.36% |
| 2006 | 103.270.000.000 | -14.94% |
| 2007 | 159.616.000.000 | 35.3% |
| 2008 | 150.236.000.000 | -6.24% |
| 2009 | 85.831.000.000 | -75.04% |
| 2010 | 49.926.000.000 | -71.92% |
| 2011 | 108.548.000.000 | 54.01% |
| 2012 | 76.607.000.000 | -41.69% |
| 2013 | 158.111.000.000 | 51.55% |
| 2014 | 106.520.000.000 | -48.43% |
| 2015 | 195.620.000.000 | 45.55% |
| 2016 | 186.964.000.000 | -4.63% |
| 2017 | 272.329.000.000 | 31.35% |
| 2018 | 206.502.000.000 | -31.88% |
| 2019 | 144.110.000.000 | -43.29% |
| 2020 | 229.402.000.000 | 37.18% |
| 2021 | 180.996.000.000 | -26.74% |
| 2022 | 239.226.000.000 | 24.34% |
| 2023 | 98.828.000.000 | -142.06% |
| 2023 | 5.944.000.000 | -1562.65% |
| 2024 | -1.397.000.000 | 525.48% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2003 | 43.377.000.000 | |
| 2004 | 48.588.000.000 | 10.72% |
| 2005 | 140.151.000.000 | 65.33% |
| 2006 | 127.930.000.000 | -9.55% |
| 2007 | 186.930.000.000 | 31.56% |
| 2008 | 197.791.000.000 | 5.49% |
| 2009 | 150.130.000.000 | -31.75% |
| 2010 | 100.639.000.000 | -49.18% |
| 2011 | 172.675.000.000 | 41.72% |
| 2012 | 144.152.000.000 | -19.79% |
| 2013 | 214.257.000.000 | 32.72% |
| 2014 | 187.686.000.000 | -14.16% |
| 2015 | 313.737.000.000 | 40.18% |
| 2016 | 235.612.000.000 | -33.16% |
| 2017 | 312.614.000.000 | 24.63% |
| 2018 | 258.630.000.000 | -20.87% |
| 2019 | 221.998.000.000 | -16.5% |
| 2020 | 306.843.000.000 | 27.65% |
| 2021 | 257.444.000.000 | -19.19% |
| 2022 | 327.767.000.000 | 21.46% |
| 2023 | 181.325.000.000 | -80.76% |
| 2023 | 36.884.000.000 | -391.61% |
| 2024 | 12.600.000.000 | -192.73% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2003 | 12.134.000.000 | |
| 2004 | 8.656.000.000 | -40.18% |
| 2005 | 21.454.000.000 | 59.65% |
| 2006 | 24.660.000.000 | 13% |
| 2007 | 27.314.000.000 | 9.72% |
| 2008 | 47.555.000.000 | 42.56% |
| 2009 | 64.299.000.000 | 26.04% |
| 2010 | 50.713.000.000 | -26.79% |
| 2011 | 64.127.000.000 | 20.92% |
| 2012 | 67.545.000.000 | 5.06% |
| 2013 | 56.146.000.000 | -20.3% |
| 2014 | 81.166.000.000 | 30.83% |
| 2015 | 118.117.000.000 | 31.28% |
| 2016 | 48.648.000.000 | -142.8% |
| 2017 | 40.285.000.000 | -20.76% |
| 2018 | 52.128.000.000 | 22.72% |
| 2019 | 77.888.000.000 | 33.07% |
| 2020 | 77.441.000.000 | -0.58% |
| 2021 | 76.448.000.000 | -1.3% |
| 2022 | 88.541.000.000 | 13.66% |
| 2023 | 82.497.000.000 | -7.33% |
| 2023 | 30.940.000.000 | -166.64% |
| 2024 | 13.997.000.000 | -121.05% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2003 | 727.855.000.000 | |
| 2004 | 743.473.000.000 | 2.1% |
| 2005 | 1.217.341.000.000 | 38.93% |
| 2006 | 1.098.995.000.000 | -10.77% |
| 2007 | 1.110.863.000.000 | 1.07% |
| 2008 | 1.030.221.000.000 | -7.83% |
| 2009 | 1.053.933.000.000 | 2.25% |
| 2010 | 1.021.096.000.000 | -3.22% |
| 2011 | 1.018.123.000.000 | -0.29% |
| 2012 | 1.062.025.000.000 | 4.13% |
| 2013 | 1.268.476.000.000 | 16.28% |
| 2014 | 1.317.916.000.000 | 3.75% |
| 2015 | 1.259.209.000.000 | -4.66% |
| 2016 | 1.271.810.000.000 | 0.99% |
| 2017 | 1.268.289.000.000 | -0.28% |
| 2018 | 1.258.396.000.000 | -0.79% |
| 2019 | 1.289.168.000.000 | 2.39% |
| 2020 | 1.386.115.000.000 | 6.99% |
| 2021 | 1.460.308.000.000 | 5.08% |
| 2022 | 1.507.954.000.000 | 3.16% |
| 2023 | 1.595.988.000.000 | 5.52% |
| 2023 | 1.639.345.000.000 | 2.64% |
| 2024 | 1.676.442.000.000 | 2.21% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2003 | 902.698.000.000 | |
| 2004 | 913.563.000.000 | 1.19% |
| 2005 | 1.584.523.000.000 | 42.34% |
| 2006 | 1.470.701.000.000 | -7.74% |
| 2007 | 1.439.152.000.000 | -2.19% |
| 2008 | 1.348.446.000.000 | -6.73% |
| 2009 | 1.364.176.000.000 | 1.15% |
| 2010 | 1.335.091.000.000 | -2.18% |
| 2011 | 1.400.629.000.000 | 4.68% |
| 2012 | 1.445.561.000.000 | 3.11% |
| 2013 | 1.653.108.000.000 | 12.55% |
| 2014 | 1.793.578.000.000 | 7.83% |
| 2015 | 1.799.338.000.000 | 0.32% |
| 2016 | 1.820.901.000.000 | 1.18% |
| 2017 | 1.858.205.000.000 | 2.01% |
| 2018 | 1.897.648.000.000 | 2.08% |
| 2019 | 2.318.160.000.000 | 18.14% |
| 2020 | 2.273.628.000.000 | -1.96% |
| 2021 | 2.332.395.000.000 | 2.52% |
| 2022 | 2.456.518.000.000 | 5.05% |
| 2023 | 3.569.603.000.000 | 31.18% |
| 2023 | 3.543.021.000.000 | -0.75% |
| 2024 | 3.735.514.000.000 | 5.15% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2003 | 174.843.000.000 | |
| 2004 | 170.090.000.000 | -2.79% |
| 2005 | 367.182.000.000 | 53.68% |
| 2006 | 371.706.000.000 | 1.22% |
| 2007 | 328.289.000.000 | -13.23% |
| 2008 | 318.225.000.000 | -3.16% |
| 2009 | 310.243.000.000 | -2.57% |
| 2010 | 313.995.000.000 | 1.19% |
| 2011 | 382.506.000.000 | 17.91% |
| 2012 | 383.536.000.000 | 0.27% |
| 2013 | 384.632.000.000 | 0.28% |
| 2014 | 475.662.000.000 | 19.14% |
| 2015 | 540.129.000.000 | 11.94% |
| 2016 | 549.091.000.000 | 1.63% |
| 2017 | 589.916.000.000 | 6.92% |
| 2018 | 639.252.000.000 | 7.72% |
| 2019 | 1.028.992.000.000 | 37.88% |
| 2020 | 887.513.000.000 | -15.94% |
| 2021 | 872.087.000.000 | -1.77% |
| 2022 | 948.564.000.000 | 8.06% |
| 2023 | 1.973.616.000.000 | 51.94% |
| 2023 | 1.903.676.000.000 | -3.67% |
| 2024 | 2.059.072.000.000 | 7.55% |
Astellas Pharma Inc. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 947.68
- Net Income per Share
- 9.68
- Price to Earning Ratio
- 179.95x
- Price To Sales Ratio
- 1.83x
- POCF Ratio
- 17.82
- PFCF Ratio
- 32.7
- Price to Book Ratio
- 1.87
- EV to Sales
- 2.24
- EV Over EBITDA
- 12.95
- EV to Operating CashFlow
- 21.7
- EV to FreeCashFlow
- 39.94
- Earnings Yield
- 0.01
- FreeCashFlow Yield
- 0.03
- Market Cap
- 3.117,04 Bil.
- Enterprise Value
- 3.806,77 Bil.
- Graham Number
- 450.87
- Graham NetNet
- -661.21
Income Statement Metrics
- Net Income per Share
- 9.68
- Income Quality
- 5.64
- ROE
- 0.01
- Return On Assets
- 0
- Return On Capital Employed
- 0.05
- Net Income per EBT
- 0.64
- EBT Per Ebit
- 0.24
- Ebit per Revenue
- 0.07
- Effective Tax Rate
- 0.26
Margins
- Sales, General, & Administrative to Revenue
- 0.34
- Research & Developement to Revenue
- 0.19
- Stock Based Compensation to Revenue
- 0
- Gross Profit Margin
- 0.8
- Operating Profit Margin
- 0.07
- Pretax Profit Margin
- 0.02
- Net Profit Margin
- 0.01
Dividends
- Dividend Yield
- 0.04
- Dividend Yield %
- 4.13
- Payout Ratio
- 7.22
- Dividend Per Share
- 72
Operating Metrics
- Operating Cashflow per Share
- 97.7
- Free CashFlow per Share
- 53.08
- Capex to Operating CashFlow
- 0.46
- Capex to Revenue
- 0.05
- Capex to Depreciation
- 0.43
- Return on Invested Capital
- 0.03
- Return on Tangible Assets
- 0.01
- Days Sales Outstanding
- 126.04
- Days Payables Outstanding
- 181.96
- Days of Inventory on Hand
- 269.08
- Receivables Turnover
- 2.9
- Payables Turnover
- 2.01
- Inventory Turnover
- 1.36
- Capex per Share
- 44.62
Balance Sheet
- Cash per Share
- 168,69
- Book Value per Share
- 933,56
- Tangible Book Value per Share
- -150.57
- Shareholders Equity per Share
- 933.56
- Interest Debt per Share
- 560.46
- Debt to Equity
- 0.59
- Debt to Assets
- 0.27
- Net Debt to EBITDA
- 2.35
- Current Ratio
- 0.9
- Tangible Asset Value
- -270,39 Bil.
- Net Current Asset Value
- -818,41 Bil.
- Invested Capital
- 2123370000000
- Working Capital
- -133,15 Bil.
- Intangibles to Total Assets
- 0.52
- Average Receivables
- 567,85 Bil.
- Average Payables
- 179,17 Bil.
- Average Inventory
- 252391500000
- Debt to Market Cap
- 0.32
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|---|---|
| 2000 | 25 | |
| 2001 | 25 | 0% |
| 2002 | 8 | -212.5% |
| 2003 | 20 | 60% |
| 2004 | 31 | 35.48% |
| 2005 | 46 | 32.61% |
| 2006 | 80 | 42.5% |
| 2007 | 90 | 11.11% |
| 2008 | 120 | 25% |
| 2009 | 120 | 0% |
| 2010 | 125 | 4% |
| 2011 | 125 | 0% |
| 2012 | 130 | 3.85% |
| 2013 | 130 | 0% |
| 2014 | 84 | -54.76% |
| 2015 | 32 | -162.5% |
| 2016 | 33 | 3.03% |
| 2017 | 35 | 5.71% |
| 2018 | 37 | 5.41% |
| 2019 | 39 | 5.13% |
| 2020 | 41 | 4.88% |
| 2021 | 46 | 10.87% |
| 2022 | 55 | 16.36% |
| 2023 | 65 | 15.38% |
| 2024 | 72 | 9.72% |
| 2025 | 0 | 0% |
Astellas Pharma Inc. Profile
About Astellas Pharma Inc.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
- CEO
- Mr. Naoki Okamura BSc
- Employee
- 14.754
- Address
-
2-5-1, Nihonbashi-Honcho
Tokyo, 103-8411
Astellas Pharma Inc. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Mr. Naoki Okamura BSc President, Chief Executive Officer & Director |
70 |
| 2 |
Mr. Nobuaki Tanaka President of Japan Commercial & Senior Corporate Executive |
70 |
| 3 |
Nobue Yasuda General Manager of Finance & Accounting Department |
70 |
| 4 |
Ms. Catherine B. Levitt General Counsel |
70 |
| 5 |
Mr. Stig Ogata Vice President of Corporate Communications |
70 |
| 6 |
Jun Kono Senior Executive Officer & Head of Japan Commercial |
70 |
| 7 |
Mr. Atsushi Kitamura Senior Executive Officer & Chief Financial Officer |
70 |
| 8 |
Mr. Katsuyoshi Sugita Chief People Officer, Chief Ethics & Compliance Officer, EVice President of HR and Representative Director |
70 |
| 9 |
Ms. Tatjana Dragovic Senior Vice President and Head of Ethics & Compliance |
70 |
| 10 |
Mr. Yoshitsugu Shitaka Ph.D. Chief Scientific Officer & Senior Managing Executive Officer |
70 |
Astellas Pharma Inc. Competitors
